Hepatocyte senescence in vivo following preconditioning for liver repopulation

Maria Paola Serra, Fabio Marongiu, Marcella Sini, Ezio Laconi – 5 March 2012 – In the retrorsine (RS)‐based model of massive liver repopulation, preexposure to this naturally occurring alkaloid is sufficient to prime normal host parenchymal cells to be slowly replaced by transplanted normal hepatocytes. The basis for this striking effect is yet to be fully elucidated. In the present studies the possible involvement of cell senescence was investigated.

Histone deacetylase 6 functions as a tumor suppressor by activating c‐Jun NH2‐terminal kinase‐mediated beclin 1‐dependent autophagic cell death in liver cancer

Kwang Hwa Jung, Ji Heon Noh, Jeong Kyu Kim, Jung Woo Eun, Hyun Jin Bae, Young Gyoon Chang, Min Gyu Kim, Won Sang Park, Jung Young Lee, Sang‐Yeop Lee, In‐Sun Chu, Suk Woo Nam – 5 March 2012 – Ubiquitin‐binding histone deacetylase 6 (HDAC6) is uniquely endowed with tubulin deacetylase activity and plays an important role in the clearance of misfolded protein by autophagy. In cancer, HDAC6 has become a target for drug development due to its major contribution to oncogenic cell transformation.

Frequency, clinical presentation, and outcomes of drug‐induced liver injury after liver transplantation

Stepan Sembera, Craig Lammert, Jayant A. Talwalkar, Schuyler O. Sanderson, John J. Poterucha, J. Eileen Hay, Russell H. Wiesner, Gregory J. Gores, Charles B. Rosen, Julie K. Heimbach, Michael R. Charlton – 5 March 2012 – Drug‐induced liver injury (DILI) is increasingly being recognized as a common cause of acute hepatitis. The clinical impact of DILI after liver transplantation (LT) is not known. The aim of this study was to describe the frequency, clinical presentation, and outcomes of DILI in LT recipients.

TAT‐apoptosis repressor with caspase recruitment domain protein transduction rescues mice from fulminant liver failure

Junfeng An, Christoph Harms, Gisela Lättig‐Tünnemann, Gernot Sellge, Ana D. Mandić, Yann Malato, Arnd Heuser, Matthias Endres, Christian Trautwein, Stefan Donath – 5 March 2012 – Acute liver failure (ALF) is associated with massive hepatocyte cell death and high mortality rates. Therapeutic approaches targeting hepatocyte injury in ALF are hampered by the activation of distinct stimulus‐dependent pathways, mechanism of cell death, and a limited therapeutic window.

Inhibition of natural killer cells protects the liver against acute injury in the absence of glycine N‐methyltransferase

Laura Gomez‐Santos, Zigmund Luka, Conrad Wagner, Sara Fernandez‐Alvarez, Shelly C. Lu, Jose M. Mato, Maria L. Martinez‐Chantar, Naiara Beraza – 5 March 2012 – Glycine N‐methyltransferase (GNMT) catabolizes S‐adenosylmethionine (SAMe), the main methyl donor of the body. Patients with cirrhosis show attenuated GNMT expression, which is absent in hepatocellular carcinoma (HCC) samples. GNMT−/− mice develop spontaneous steatosis that progresses to steatohepatitis, cirrhosis, and HCC.

Case‐control study of hepatitis B and hepatitis C in older adults: Do healthcare exposures contribute to burden of new infections?

Joseph F. Perz, Scott Grytdal, Suzanne Beck, Ana Maria Fireteanu, Tasha Poissant, Elena Rizzo, Katherine Bornschlegel, Ann Thomas, Sharon Balter, Jeremy Miller, R. Monina Klevens, Lyn Finelli – 2 March 2012 – Reports of hepatitis B virus (HBV) and hepatitis C virus (HCV) transmission associated with unsafe medical practices have been increasing in the United States. However, the contribution of healthcare exposures to the burden of new infections is poorly understood outside of recognized outbreaks.

Congenital heart disease and the liver

Sumeet K. Asrani, Nina S. Asrani, Deborah K. Freese, Sabrina D. Phillips, Carole A. Warnes, Julie Heimbach, Patrick S. Kamath – 2 March 2012 – There are approximately 1 million adult patients with congenital heart disease (CHD) in the United States, and the number is increasing. Hepatic complications are common and may occur secondary to persistent chronic passive venous congestion or decreased cardiac output resulting from the underlying cardiac disease or as a result of palliative cardiac surgery; transfusion or drug‐related hepatitis may also occur.

Pegylated interferon for chronic hepatitis C in children affects growth and body composition: Results from the pediatric study of hepatitis C (PEDS‐C) trial

Maureen M. Jonas, William Balistreri, Regino P. Gonzalez‐Peralta, Barbara Haber, Steven Lobritto, Parvathi Mohan, Jean P. Molleston, Karen F. Murray, Michael R. Narkewicz, Philip Rosenthal, Kathleen B. Schwarz, Bruce A. Barton, John A. Shepherd, Paul D. Mitchell, Christopher Duggan – 2 March 2012 – Weight loss and changes in growth are noted in children treated with interferon alpha (IFN‐α). The aim of this study was to prospectively determine changes in weight, height, body mass index (BMI), and body composition during and after treatment of children with hepatitis C virus (HCV).

Subscribe to